ReviewOncology reviews2026
Models of high-grade serous carcinoma of tubo-ovarian origin.
Review in Oncology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-read, whole-genome sequencing and chemotherapy response of two patient-derived organoids from a TP53- and KRAS-mutant ovarian carcinoma.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Biological models aim to recapitulate the molecular and histologic characteristics, as well as the carcinogenesis of the disease of interest, to enable high-fidelity experimentation and impactful translational development. In high-grade serous carcinoma of ovarian, tubal, or peritoneal origin, there is a need to regularly re-evaluate the experimental models being employed to address research questions. This review aims to provide a resource for better understanding the applications, strengths, and limitations of the available models. This work discusses the origin and carcinogenesis of high-grade serous carcinoma and reviews normal cell-of-origin models, as understanding the cellular origin is critical to experimental efforts focused on pathogenesis, disease progression, and prevention. High-grade serous carcinoma cell lines are discussed, including essential and complementary molecular features, cell line management, and limitations. Next, the review examines advances in organoids, with a specific focus on patient-derived organoids from ascites and single-cell suspensions, organ-on-a-chip platforms, and tissue slice technologies. Finally, given the heterogeneity of epithelial ovarian cancer in general, and high-grade serous carcinoma in particular, and the evolving understanding of the importance of the tumor microenvironment,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.